Predictors of the effects of 4years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency - a KIMS database analysis

被引:13
|
作者
Tritos, Nicholas A. [1 ,2 ]
Hamrahian, Amir H. [3 ]
King, Donna [4 ]
Greenspan, Susan L. [5 ]
Cook, David M. [6 ]
Jonsson, Peter J. [7 ]
Koltowska-Haggstrom, Maria [7 ]
Biller, Beverly M. K. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Cleveland Clin, Dept Diabet Endocrinol & Metab, Cleveland, OH 44106 USA
[4] Pfizer Inc, New York, NY USA
[5] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA
[6] Oregon Hlth & Sci Univ, Dept Endocrinol, Portland, OR 97201 USA
[7] Pfizer Inc, Pfizer Endocrine Care, Sollentuna, Sweden
关键词
GH REPLACEMENT; GLUCOCORTICOID REPLACEMENT; HYPOPITUITARY PATIENTS; POSTMENOPAUSAL WOMEN; BODY-COMPOSITION; METABOLISM; THERAPY; 2-YEAR; MASS; MULTICENTER;
D O I
10.1111/cen.12132
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Growth hormone (GH) replacement may increase bone mineral density (BMD) in GH-deficient (GHD) adults. The goal of this study was to identify predictors of BMD response to GH replacement in GH naive adults. Design and measurements This was a retrospective analysis of data extracted from KIMS (Pfizer International Metabolic Database), an international pharmacoepidemiological survey of adult GHD patients from 31 countries. Patients A total of 231 GH naive adults were identified (115 women and 116 men) who had BMD measured on the same densitometer in the lumbar spine (LS) and/or femoral neck (FN) both at baseline and after 4 years of GH replacement. Results After 4 years, there was a median (10th, 90th percentile) 4.6% (-5.2%, 12.2%) increase in LS BMD over baseline (P = 0.0001). There was a positive correlation between per cent change in LS BMD and age at the onset of pituitary disease (r = 0.25, P = 0.001). There was no change in FN BMD over baseline [0.0% (-7.3%, 8.5%)]. On multivariate analysis, older age at the onset of pituitary disease predicted a greater increase in LS BMD on GH replacement (r = 0.55, P < 0.0001). Conclusions In a population of GH naive adults, GH replacement led to a significant increase in LS BMD over baseline, but no change in FN BMD. The potential for greater BMD improvement on GH replacement therapy in adults with disease of later onset should be considered when making treatment decisions in this patient population.
引用
收藏
页码:178 / 184
页数:7
相关论文
共 50 条
  • [31] Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: Results of a double-blind placebo-controlled study with open follow-up
    Finkenstedt, G
    Gasser, RW
    Hofle, G
    Watfah, C
    Fridrich, L
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1997, 136 (03) : 282 - 289
  • [32] Growth hormone replacement therapy reduces risk of cancer in adult with growth hormone deficiency: A meta-analysis
    Li, Zhanzhan
    Zhou, Qin
    Li, Yanyan
    Fu, Jun
    Huang, Xinqiong
    Shen, Liangfang
    ONCOTARGET, 2016, 7 (49) : 81862 - 81869
  • [33] Seven years of follow up of trabecular bone score, bone mineral density, body composition and quality of life in adults with growth hormone deficiency treated with rhGH replacement in a single center
    Allo Miguel, Gonzalo
    Serraclara Pla, Alicia
    Partida Munoz, Myriam Lorena
    Martinez Diaz-Guerra, Guillermo
    Hawkins, Federico
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2016, 7 (03) : 93 - 100
  • [34] Effects of 3-year GH replacement therapy on bone mineral density in younger and elderly adults with adult-onset GH deficiency
    Elbornsson, Mariam
    Gotherstrom, Galina
    Franco, Celina
    Bengtsson, Bengt-Ake
    Johannsson, Gudmundur
    Svensson, Johan
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 166 (02) : 181 - 189
  • [35] Special issue 15 years of KIMS® and 5 years of ACROSTUDY™ Their contribution to the management of adult patients with growth hormone disorders Foreword
    Wilton, Patrick
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2009, 161 : S1 - S2
  • [36] Long-term metabolic effectiveness and safety of growth hormone replacement therapy in patients with adult growth hormone deficiency: a single-institution study in Japan
    Oi-Yo, Yuka
    Yamamoto, Masaaki
    Urai, Shin
    Bando, Hironori
    Ohmachi, Yuka
    Motomura, Yuma
    Kobatake, Masaki
    Tsujimoto, Yasutaka
    Sasaki, Yuriko
    Suzuki, Masaki
    Yamamoto, Naoki
    Takahashi, Michiko
    Iguchi, Genzo
    Ogawa, Wataru
    Takahashi, Yutaka
    Fukuoka, Hidenori
    PITUITARY, 2024, 27 (05) : 605 - 613
  • [37] Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis
    Abs, Roger
    Mattsson, Anders F.
    Thunander, Maria
    Verhelst, Johan
    Goth, Miklos I.
    Wilton, Patrick
    Koltowska-Haggstrom, Maria
    Luger, Anton
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2013, 168 (03) : 297 - 305
  • [38] Effects of aerobic exercise on ectopic lipids in patients with growth hormone deficiency before and after growth hormone replacement therapy
    Christ, Emanuel R.
    Egger, Andrea
    Allemann, Sabin
    Buehler, Tania
    Kreis, Roland
    Boesch, Chris
    SCIENTIFIC REPORTS, 2016, 6
  • [39] Characterisation of myocardial structure and function in adult-onset growth hormone deficiency using cardiac magnetic resonance
    Thomas, Julia D. J.
    Dattani, Abhishek
    Zemrak, Filip
    Burchell, Thomas
    Akker, Scott A.
    Gurnell, Mark
    Grossman, Ashley B.
    Davies, L. Ceri
    Korbonits, Marta
    ENDOCRINE, 2016, 54 (03) : 778 - 787
  • [40] Socioeconomic Factors Do Not but GH Treatment Does Affect Mortality in Adult-Onset Growth Hormone Deficiency
    Stochholm, Kirstine
    Berglund, Agnethe
    Juul, Svend
    Gravholt, Claus Hojbjerg
    Christiansen, Jens S.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (11): : 4141 - 4148